MINERALYS THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification and Advancement Agreement • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Mineralys Therapeutics, Inc. a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement of expenses.
ContractMineralys Therapeutics, Inc. • January 18th, 2023 • Pharmaceutical preparations • California
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential.
MINERALYS THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 8th, 2024 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (the “Agreement”) is made as of February 7, 2024 (the “Effective Date”), by and between Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers whose names and addresses are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
Re: Amended and Restated Employment LetterLetter Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Colorado
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated March 8, 2022, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the date on which the registration statement on Form S-1 filed in connection with the Company’s initial public offering (“IPO”) becomes effective. In consideration of the mutual promises herein contained, the parties agree as follows:
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 2nd, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 1, 2022, as amended, by and among Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on Schedule A hereto (each, an “Investor”).
ContractMineralys Therapeutics, Inc. • January 18th, 2023 • Pharmaceutical preparations • Colorado
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENTLicense Agreement • January 18th, 2023 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) made and executed as of [***], by and between Mitsubishi Tanabe Pharma Corporation, a corporation organized under the laws of Japan and having its principal place of business at 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka 541-8505, Japan (“MTPC”), and Mineralys Therapeutics, Inc., a corporation organized under the laws of the state of Delaware and having its principal of business at 100 Pine Street, Suite 1250, San Francisco, CA 94111, U.S.A. (“MINERALYS”). MTPC and MINERALYS are sometimes referred to individually as a “Party” and collectively as “Parties”.
MINERALYS THERAPEUTICS, INC. Common Stock ($0.0001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENTEquity Offeringsm Sales Agreement • March 21st, 2024 • Mineralys Therapeutics, Inc. • Pharmaceutical preparations • New York
